Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial details
- Registry ID
- NCT04773587
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ARQ-151
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisNCT04773587 | ARQT | Phase 3 | Completed | 2022-08-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |